الصفحة الرئيسية>>Signaling Pathways>> Apoptosis>> Other Apoptosis>>PD0166285

PD0166285

رقم الكتالوجGC32853

PD0166285 ، ركيزة P-gp ، هو مثبط WEE1 ومثبط Myt1 ضعيف بقيم IC50 24 و 72 نانومتر ، على التوالييعرض PD0166285 IC50 بمقدار 3.433 ميكرومتر لـ Chk1

Products are for research use only. Not for human use. We do not sell to patients.

PD0166285 التركيب الكيميائي

Cas No.: 185039-89-8

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
156٫00
متوفر
5mg
138٫00
متوفر
10mg
220٫00
متوفر
25mg
496٫00
متوفر
50mg
864٫00
متوفر
100mg
1517٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

PD0166285 is a WEE1 inhibitor and a weak Myt1 inhibitor with IC50s of 24 and 72 nM, respectively.

PD0166285 is a pyridopyrimidine class of molecule. At the cellular level, 0.5 μM PD0166285 dramatically inhibits irradiation-induced Cdc2 phosphorylation at the Tyr-15 and Thr-14 in seven of seven cancer cell lines. PD0166285 sensitizes radiation-induced cell killing in p53 mutant HT29 cells and in the E6-transfected, p53-null ovarian cancer cell line PA-1 but to a lesser extent in p53 wild-type PA-1 cells. PD0166285 abrogates irradiation-induced G2 arrest and significantly increases mitotic cell populations. Biologically, PD0166285 acts as a radiosensitizer to sensitize cells to radiation-induced cell death with a sensitivity enhancement ratio of 1.23[1].

[1]. Wang Y, et al. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res. 2001 Nov 15;61(22):8211-7.

مراجعات

Review for PD0166285

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PD0166285

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.